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Abstract
Mounting evidence from human, animal, and in vitro studies indicates that existing drugs,
developed to treat other disorders, might also be effective in preventing or slowing the progression
of diabetic nephropathy to end stage renal disease. Examples of such drugs include the urate-
lowering agent allopurinol, the anti-TNF agents etanercept and infliximab, and the immuno-
modulating drug abatacept. Since some these medications are already on the market and have been
used for a number of years for other indications, they can be immediately tested in humans for a
beneficial effect on renal function in diabetes. Special emphasis should be placed on evaluating
the use of these drugs early in the course of diabetic nephropathy when renal damage is most
likely to be reversible and interventions can yield the greatest delay to end stage renal disease.
Keywords
diabetic nephropathy; uric acid; inflammation; immune system; novel therapeutics
Introduction
Diabetic nephropathy is the long-term complication of diabetes that imposes the highest
social and economic burden, being one of the main causes of end stage renal disease
(ESRD).1 Despite improvements in glycemic and blood pressure control, and the
introduction of renin–angiotensin system (RAS) blockers, the overall risk of diabetic
© 2012 Elsevier Inc. All rights reserved.
Address for correspondence: Alessandro Doria, MD, PhD, MPH, Section on Genetics and Epidemiology, Joslin Diabetes Center,
One Joslin Place, Boston, 02215, MA, USA, Tel: 617-309-2406, Fax: 617-309-2667, alessandro.doria@joslin.harvard.edu, or, Paolo
Fiorina, MD PhD, Transplantation Research Center, Nephrology Division, Children’s Hospital, Harvard Medical School, 300
Longwood Ave., Enders 5th floor, Room En530, Boston, 02215, MA, USA, Tel: 617-919-2624, Fax: 617-732-5254,
paolo.fiorina@childrens.harvard.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosure statement: AD, MAN, and PF have nothing to declare.
NIH Public Access
Author Manuscript
Semin Nephrol. Author manuscript; available in PMC 2013 September 01.
Published in final edited form as:
Semin Nephrol. 2012 September ; 32(5): 437–444. doi:10.1016/j.semnephrol.2012.07.006.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
nephropathy in the population is not declining.2–4 Thus, novel therapeutic approaches are
urgently needed to complement glycemic control and RAS inhibition.
One approach is to identify novel drug targets by gaining a better understanding of the
pathogenesis of diabetic nephropathy at the molecular level, as discussed by other articles in
this issue5–7. However, going from the identification of a drug target to the development of a
clinically effective intervention is a long and costly process and only a small number of
compounds that enter the development pipeline end up being approved for clinical use. The
process is further complicated in the case of diabetic nephropathy by the lack of good animal
models, as discussed by Breyer in this issue8.
A complementary strategy is to investigate whether existing drugs, developed and approved
for other indications, may have as yet unknown therapeutic effects on diabetic nephropathy.
The most obvious advantage of this approach is that clinical trials of these drugs, if justified,
can be started at once. Other benefits include the extensive postmarketing surveillance
conducted for many of these compounds, reducing the possibility of unknown side effects,
and the fact that some of these drugs are inexpensive owing to their long presence on the
market and their availability as generic preparations.
Some examples of existing drugs that could be tested for a beneficial effect on diabetic
nephropathy are reported in Table 1. Below we examine the evidence suggesting that these
medications might be effective in preventing or slowing down kidney damage in diabetes
and discuss how clinical trials of these drugs should be designed in order to maximize their
probabilities of success.
Drugs targeting metabolic pathways
One possible strategy is to target metabolic pathways that are not involved in the etiology of
diabetic nephropathy, but modulate the susceptibility of the kidney to the deleterious effects
of hyperglycemia. Existing interventions in this category that have been investigated in
clinical trials include B-vitamins, to decrease homocystinemia9–11, and statins, to decrease
cholesterolemia12,13. While neither of these treatments has yielded the expected
benefits14–17, new hope for such adjuvant therapies has recently come from the finding of a
link between uric acid and progression of kidney damage in diabetes.
In the Second Joslin Kidney Study (JKS), elevated baseline serum uric acid was one of the
strongest independent predictors of early GFR in diabetes18. In this prospective study,
including 355 Joslin patients with micro- or high-normoalbuminuria and estimated GFR ≥
60 ml/min at baseline, a direct dose-response relationship was observed between baseline
serum uric acid levels and subsequent risk of early increased GFR loss, defined as a rate of
GFR decline above the 97.5th percentile of the distribution in the general population (Figure
1). The unadjusted odds ratio was 1.5 (95% CI 1.3–1.9, p=0.0002) for each mg/dl increase in
serum uric acid, which translates into a ~2-fold increase in the risk of early GFR loss for a
serum uric acid levels ≥ 5 mg/dl as compared to levels <5 mg/dl. The magnitude of this
effect did not significantly change after adjustment for urinary AER, gender, HbA1c, or,
importantly, baseline GFR. Serum uric acid also predicted the transition from
normoalbuminuria to micro- or macro-albuminuria in the Coronary Artery Calcification in
Type 1 Diabetes Study19,20. As in the JKS, the effect of uric acid was not influenced by
adjustment for other baseline variables. Similarly, in a study from Denmark, the uric acid
level shortly after the onset of type 1 diabetes was a significant independent predictor of
macroalbuminuria 18 years later21.
The prospective nature of these findings and their robustness to adjustment for potential
confounders strongly suggest that moderately elevated serum uric acid may play a causal
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role by favoring the deterioration of kidney function caused by the diabetic milieu.
Alterations of nitric oxide (NO) pathways and induction of pro-inflammatory cytokines22,23,
and increased oxidative stress resulting from the generation of uric acid by xanthine
oxidase24,25 could be responsible for this effect. Two small clinical trials have recently
provided proof of concept data for translating these findings into a novel intervention. One
of these study was from Hong-Kong and included 51 subjects (25% of whom with diabetes)
having CKD Stage 3 or higher, who were treated with allopurinol for 12 months26. At the
end of the intervention, about 20% of individuals in the allopurinol group had had a
significant increase in serum creatinine as opposed to about 70% in the placebo group. The
other study was from Spain and included 113 subjects with CKD stage 3 or higher, who
were treated with allopurinol for 24 months27. About 15% of the participants had diabetes.
During the trial, GFR increased by 1 ml/min in the allopurinol group as compared to a 3 ml/
min loss in the placebo group. A beneficial effect of urate-lowering drugs on the progression
of kidney disease has also been observed in animal models28.
The availability of a safe and inexpensive uric acid-lowering drug such as allopurinol makes
this intervention especially attractive. Allopurinol is an inhibitor of xanthine oxidase, which
is responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid. It
has been on the market since 1964 as the main drug for the prevention of gout in
hyperuricemic subjects and the prevention of acute urate nephropathy and gout in patients
receiving chemotherapy for cancer. At the average dosage (300 mg/day), allopurinol causes
a 30–40% reduction in serum UA29–31, but up to a 60% reduction can be obtained using the
maximum dosage of 600 mg.32 Skin rashes, usually maculopapular, are the most commonly
reported adverse effect. Rashes may be followed by more severe hypersensitivity reactions
such as exfoliative lesions and the Stevens-Johnson syndrome, but such occurrence is very
rare, in the order of 1 in 10,00033. Other potential adverse effects include gout flares (if
there is a history of gout), hepatotoxicity, and, rarely, bone marrow depression. A new uric
acid-lowering drug (febuxostat) that does not have the skin side effects of allopurinol has
become recently available30, although its cardiovascular safety is still being investigated
(NCT01101035).
Drug targeting inflammatory pathways
Inflammation, as indicated by the presence of inflammatory cells in the tubulointerstitium,
has been known for many years to occur in the diabetic kidneys. Indeed, a number of studies
have shown that in diabetic subjects the degree of tubulointerstitial injury correlates better
with the impairment of renal function than the degree of glomerular damage34–36. In
agreement with these findings, prospective studies have shown that increase urinary levels
of tubular and inflammatory markers such as kidney injury molecule-1 (KIM1) and
monocyte chemotactic protein-1 (MCP-1) accompany the progression of diabetic
nephropathy37,38. The demonstration in animal models that lymphocytes are not essential for
these changes points to a key role of innate immunity in this process39 and suggests that
drugs targeting these pathways could exert a beneficial effect in preserving renal function in
diabetes.
Macrophages are the major inflammatory cells infiltrating the kidney in diabetic
nephropathy40. Accumulation and activation of these cells have been described in the
kidneys of db/db mice with proteinuria, their extent being correlated with hyperglycemia,
HbA1c levels, albuminuria, elevated plasma creatinine, glomerular and tubular damage,
renal fibrosis, and kidney expression of macrophage chemokines41. Interestingly, some of
the beneficial effects of drugs commonly used in diabetes appear to result from their
capacity to interfere with macrophage functions. For instance, angiotensin II receptor
blockers and ACE inhibitors reduce macrophage-mediated injury in diabetic nephropathy by
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down-regulating macrophage NF-kB signaling42. Other agents that interfere with
macrophage functions could be similarly useful to prevent diabetic nephropathy. An
example is MMF – an immunosuppressant that was shown to inhibit kidney macrophage
accumulation and diabetic nephropathy severity in Zucker rats43. An especially attractive
target is MCP-1 - a chemokine having potent chemoattractive effects on macrophages.
Inhibition of MCP-1 or its receptor reduces interstitial inflammation and macrophage
accumulation in experimental models of diabetes44–46. An MCP-1 inhibitor – Bindarit - has
been demonstrated to reduce albuminuria in active lupus nephritis47 and a phase II study of
this drug in albuminuric subjects with type 2 diabetes has just been completed
(NCT01109212), although results have not been made public yet.
Another strategy is to use drugs acting on the development of interstitial fibrosis, the sequela
of inflammation that is in the end responsible for the loss of kidney function. One such drug
is pirfenidone – an inhibitor of TGF-β production that has been shown to decrease matrix
deposition in experimental models of kidney disease48. In a small, exploratory study, this
compound had beneficial effects on GFR decline in both type 1 and type 2 diabetic subjects
with advanced diabetic nephropathy, but these findings must be validated in larger studies49.
Additional suggestions about possible targets are expected from epidemiological studies. In
this regard, a recent cohort study including over a thousand patients with both types of
diabetes attending the Joslin Clinic has shown that elevated circulating levels of TNF
receptors 1 and 2 are strong, independent predictors of subsequent kidney function loss50,51.
The predictive power of these two inflammatory markers was much stronger than that of
other markers of endothelial dysfunction and inflammation or other components of the TNF
pathway including TNFα itself. The role of TNFα is well recognized in the etiology of
rheumatoid arthritis and TNFα inhibitors, such as etanercept or infliximab, are routinely
used in the treatment of this disease52. There is also a body of literature supporting a role of
TNFα in the etiology of diabetic nephropathy53. However, the findings from the Joslin
study raise the question as of whether interventions in diabetic nephropathy should be
specifically focused on TNF receptors rather than on the TNF pathway in general. In support
of this hypothesis, in vitro exposure of human kidney cells to soluble TNF receptors triggers
cell death even in the absence of TNF α in the medium54. Furthermore, TNFR1 and TNFR2
knockout mice show a delay in the fibrotic response in experimental models of
tubulointerstitial fibrosis55. A new antagonist of TNF receptors (progranulin), inhibiting the
interaction between TNFα and TNFRs in a dose-dependent manner, has been recently
identified through a global genetic screening56. This molecule and its engineered derivative
Atsttrin have been shown to delay the course of rheumatoid arthritis in animal studies57.
Thus, one can hypothesize that TNFR inhibition may become an attractive therapeutic tool
to evaluate for the prevention of ESRD in diabetes in the near future.
Drug targeting immunological mechanisms
While diabetic nephropathy has never been considered an immunological disease, several
reports in the literature have recently raised the possibility that immune-related mechanisms
may be involved in its pathogenesis58,59.
T-cells have been found in the kidneys of animal models of diabetic nephropathy60,
probably recruited into this organ by the overexpression of MCP-1, CX3CL1, and ICAM-1
by inflamed endothelial cells61. Since T-cell depletion affects the development and the
natural history of renal damage in animal models62, drugs that target these cells (e.g., anti-
CD3 mAb or ATG) or abrogate their proliferation/activation may have a use for diabetic
nephropathy, even though they should probably be reserved to high risk patients (e.g.; fast
decliners) given the potential for severe adverse events63. Interventions targeting B-cells are
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also available, but the evidence for a role of these cells in diabetic nephropathy is not as
clear cut as for T-cells.
In addition to immune cells infiltrating the kidney, a variety of immune-related molecules
have been found to be expressed by non-immune cells such as podocytes, mesangial cells,
and tubular cells and to be upregulated in response to high-glucose or other stresses. For
instance, Gutwein et al. found that cytokines such as IFN-γ and TNF-α induce podocyte
expression of CXCL16 and ADAM10, which may in turn chemoattract T-cells64. Also,
Huber et al. demonstrated that human podocytes, either grown in culture or isolated from
biopsies, express many chemokines’ receptors, including CCR4, CCR8, CCR9, CCR10,
CXCR1, CXCR3, CXCR4, and CXCR565. Podocytes also express CD80 (B7.1) in response
to LPS and other types of stress, and lack of this molecule significantly reduces LPS-
mediated podocyte injury66. Studies are underway to determine whether podocytes respond
in a similar way to high glucose. If this is the case, one could hypothesize the use of
CTLA4-Ig (Abatacept) – a molecule that binds and blocks B7.1 on podocytes – as a
therapeutic approach to diabetic nephropathy. This drug has been safely tested in patients
with new onset type 1 diabetes in a study aimed at delaying C-peptide loss67. In this
multicenter trial, patients with recently diagnosed type 1 diabetes were randomly assigned to
abatacept (10 mg/kg) or placebo administered intravenously on days 1, 14, 28, and monthly
for a total of 27 infusions over 2 years. Abatacept-treated subjects experienced few infusion-
related adverse events (22% in patients on abatacept and 17% in those on placebo) and did
no show any increase in the risk of infections (42% vs. 43% in the abatacept vs. the placebo
group, respectively) or neutropenia (9% vs. 14%). Thus, abatacept seems to be as safe as
placebo when used in mono-therapy. In view of these findings and the extensive clinical
trials of Abatacept for immune-related kidney diseases (Table 2) and Belatacept (which
differs from Abatacept by only 2 aminoacids and binds both CD80/B7.1 and CD86/B7.2) in
kidney-transplanted patients, these drugs appear as the most attractive immuno-modulatory
interventions for diabetic nephropathy. Of note, B7.1/CD80 and CD86/B7.2 are also
expressed on human tubular cells during inflammation where they may interact with their
ligand CD28, either soluble or expressed by T-cells, and lead to the loss or damage of
tubular cells68. Thus, blockage of B7.1 and of B7.2 may also have a benefit at this level in
addition to that on podocytes.
Clinical trials to test the efficacy of existing drugs
Since many of the drugs discussed above have been already approved for other indications,
their effect on diabetic nephropathy can be readily tested in randomized clinical trials. It is
crucial, however, that these trials are properly designed in order to maximize power and to
exploit the full potential of these drugs to prevent or retard renal function loss.
Target population
One important aspect concerns the selection of the individuals to whom these interventions
should be applied. As illustrated in detail in the introductory issue of this article69, the rate
of renal function decline varies widely among the diabetic subjects who progress to ESRD,
suggesting heterogeneity in the underlying mechanisms of kidney damage. It is also likely
that the molecular pathways involved in the etiology of kidney damage undergo changes as
the renal function declines from norml to ESRD. Thus, candidate drugs should be tested in
specific groups of diabetic subjects defined on the basis of their rate of kidney function loss
(e.g., rapid progressors vs. slow progressors) and their stage of renal function loss (e.g.,
early vs. late). For each drug, the group of patients to be targeted should be decided on the
basis of the evidence from human and animal studies concerning the role of the drug target
in the progression of kidney disease.
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Interventions that may be effective at the early stages of renal fucntion loss are especially
attractive since these can yield the greatest delay to ESRD. If a diabetic patient loses GFR at
a constant rate of 4 ml/min per year, a 50% reduction in that rate of decline will delay
reaching ESRD (GFR ≤ 15 ml/min) by 20 years if the intervention is started when the GFR
is 90 ml/min, as opposed to a delay of only 8 years if the intervention is started when the
GFR is 45 ml/min. For young type 1 diabetic patients with kidney complications, such as
that depicted in Figure 2, this may make the difference between developing ESRD in their
70s as opposed to their 50s. A potential argument against early interventions is that a good
proportion of the diabetic patients with mild to moderately decreased GFR may be “slow
progressors” who will never reach ESRD. Thus, one may need to treat a large number of
them to prevent ESRD in the relatively small proportion at risk. However, biomarkers, such
as serum uric acid in the case of allopurinol18 or TNF receptors for drugs targeting the TNF
system50,51, are often available to identify individuals who are at greater risk of loosing
GFR and would specifically benefit from the interventions under consideration. This is in
addition to increased albuminuria, which can also be used to select higher risk candidates for
early interventions.
Response/outcome variable
Past clinical trials of therapies for diabetic nephropathy have often used albuminuria as the
response variable. However, prospective studies have shown that, in a substantial proportion
of type 1 diabetes patients, there may be a dissociation between natural history of renal
function and that of albuminuria.70–72 Since it is the loss of renal function that drives the
increased morbidity and mortality associated with diabetic nephropathy, it seems obvious
that this, rather than albuminuria, should be the outcome on which the efficacy of an
intervention is measured. If the goal is to intervene early, as we have argued in the previous
paragraph, the most effective response variable would be the GFR at the end of the
intervention considered on a continuous scale after adjustment for the baseline value. This
approach is equivalent to comparing pre- to post-treatment changes in GFR between
treatment arms, but yields greater power when the correlation between pre- and post-
treatment values is only moderate73. A related approach is to measure the GFR at different
time points in order to estimate the slope of GFR decline during the intervention period. The
problem with this strategy, however, is that GFR slopes may be unduly influenced by
transitory changes in the GFR early in the course of treatment as discussed by Stevens et
al.74. Furthermore, the methods for comparing slopes are more complex, since they involve
the analysis of time × treatment interactions. Such complexity may offset the gain in power
provided by the multiple GFR measures. Survival analyses based on hard endpoints, such as
ESRD or serum creatinine doubling, are not useful for the study of interventions on early
GFR loss since an extremely long trial duration and large sample size would be required in
order to have enough events for a meaningful comparison between treatment arms. For
instance, an untreated patients having a baseline GFR of 80 ml/min and losing GFR at a
constant rate of 4 ml/min/year would need 12 years to experience a doubling of serum
creatinine and 17 years to reach ESRD. It should be added that it is not strictly necessary to
demonstrate efficacy on hard endpoints in the case of drugs that are already on the market
and for which there is no interest in applying to the FDA for a new indication. If such
evidence is needed, as in the case of a new drug, one approach can be to restrict the study
population to subjects who have a GFR closer to the end-point and are at especially high risk
of losing renal function based their previous clinical history or biomarker profile.
Time frame
Another important aspect concerns the optimal duration of the trial. Many of the trials
conducted thus far have been relatively short, mostly being less than two year long, in order
to minimize attrition and contain financial and human costs. However, it is critical that trials
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are long enough to go beyond functional, short-term effects that drugs may have on GFR74.
Even more importantly, the longer is the trial, the larger are the differences in GFR that can
be attained between treatment arms, increasing the power of the study for any given sample
size.
Summary and conclusions
Despite the progress that has occurred during the pat 20 years, preventing end stage renal
disease in diabetes is still an unmet need. While research is ongoing to develop new
medications, several drugs that are already on the market for the treatment of metabolic,
inflammatory, and immunological disorders can be hypothesized to have beneficial effects
on diabetic nephropathy based on the known links between their molecular targets and
kidney damage in diabetes. Given their known safety profile, some of these drugs could and
should be immediately tested for a beneficial effect on kidney function in humans. In doing
so, we should take the opportunity to rethink the design of diabetic nephropathy clinical
trials in order to increase power and maximize the impact of interventions on the natural
history of kidney disease in diabetes.
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Figure 1.
Risk of early GFR loss in the JKS during 4–6 years of follow-up according to baseline
serum UA levels (from Ficociello et al.)
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Figure 2.
GFR trajectory of a hypothetical type 1 diabetes patients who developed diabetes at age 10
and started to lose renal function at age 25 at a constant rate of 4 ml/min per year. The solid
line represents the GFR trajectory without treatment, the dotted lines are the trajectories with
an intervention that reduce GFR decline from 4 to 2 ml/min/year and is started at a GFR of
90 ml/min or at a GFR of 45/ml/min.
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Figure 3.
Course of urinary albumin excretion (triangles) and renal function (circles) over the 14 years
preceding the onset of CKD3 in a Joslin type 1 diabetic patient.
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Table 1
Examples of existing drugs that could have an application in preventing or halting the progression of diabetic
nephropathy.
Drugs Target Current indication Generic available
Allopurinol Uric Acid Gout, chemotherapy-induced hyperuriciema Yes
Febuxostat Uric Acid Gout, chemotherapy-induced hyperuriciema No
Etanercept TNFα Rheumatoid and psoriatic arthritis, plaque psoriasis,
ankylosing spondylitis
No
Infliximab TFNα Rheumatoid and psoriatic arthritis, plaque psoriasis,
ankylosing spondylitis, Crohn's disease, ulcerative
colitis
No
Atsttrin TNFα receptors Human experimentation in progress. No
Sirolimus mTor pathway Prevention of transplant rejection Yes (Canada)
Basiliximab CD25 Prevention of transplant rejection No
Mycophenolate mofetil (MMF) IMPDH (purine biosynthesis) Antoimmune disorders, prevention of transplant
rejection
No
Abatacept CD80/B7.1 Rheumatoid arthritis No
Belatacept CD80/B7.1 and CD86/B7.2 Prevention of transplant rejection No
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Table 2
Clinical Trial with CTLA4-Ig (Abatacept) in kidney/immunological diseases. Abatacept (marketed as
Orencia) is a fusion protien generated with an immunoglobulin fused to the extracellular domain of CTLA4
and capable of stable binding to B7.1/CD80, thus blocking its activation.
Study/Identifier Purpose Status/PI
Efficacy and Safety Study of
Abatacept to Treat Lupus
Nephritis
NCT00430677
The purpose of this clinical research study is to learn if abatacept
treatment of patients with active lupus nephritis who are also taking
mycophenolate mofetil (MMF) and steroid as part of this study will
control the nephritis despite a protocol-defined steroid taper; the
endpoint is "confirmed complete renal response", a composite
including stabilization or improvement of renal function,
improvement of proteinuria, and improvement of urinary sediment.
The safety of this treatment will also be studied
Ongoing Bristol-Myers Squibb
Abatacept and
Cyclophosphamide
Combination Therapy for
Lupus Nephritis (ACCESS)
NCT00774852
This study is for people with lupus who have developed
complications in their kidneys, or lupus nephritis. The study will
determine whether adding the experimental medication abatacept to
standard cyclophosphamide therapy is more effective in improving
lupus nephritis than standard cyclophosphamide therapy by itself
Ongoing David wofsy,, University of
California, San Francisco Betty
Diamond, MDFeinstein Institute
Abatacept in Treating Adults
With Mild Relapsing
Wegener's Granulomatosis
NCT00468208
Wegener's granulomatosis (WG) is a rare disease that causes
inflammation of blood vessele, or vasculitis. It may involve many
different parts of the body, but typically affects the upper and lower
respiratory tract and kidneys. The purpose of this study is to
determine the safety and effectiveness of the medication abatacept
in treating adults with mild relapsing WG
Ongoing
Carol A. Langford, The Cleveland
Clinic Peter A. Merkel, Boston
University
Abatacept in ANCA
Associated Vasculitis
(ABAVAS)
NCT00482066
The purpose of this study is to investigate whether abatacept can
prevent relapse in patients with ANCA associated vasculitis(AAV).
This is a randomised double blined placebo controlled trial
Terminated Alan Salama Imperial
College London
Intravenous CTLA4-Ig
Treatment in Recent Onset
Type 1 Diabetes Mellitus
NCT00505375
The purpose of this study is to determine whether treatment with
CTLA4-Ig (Abatacept) in individuals with new onset T1DM will
improve insulin secretion (C-peptide production) compared to
placebo
Ongoing Tihamer Orban, joslin
Diabetes Center
Islet Transplantation Using
Abatacept
NCT00276250
Islet transplantation in type 1 diabetices with hypoglycemic
unawareness using abatacept as a part of a novel calcineurin-
inhibitor-sparing immunosuppressive regimen.
Ongoing Christian P Larsen/Thomas C
Pearson Emory University
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